glp-1 adherence Platforms Market, Growth and Forecast 2036 Most Patients Discontinue GLP-1 Drugs

Research has proven them effective for both conditions, and theyre a great alternative to injectable options like Ozempic or Wegovy

and Bydureon, AstraZeneca), liraglutide (Victoza, Novo Nordisk), lixisenatide (Adlyxin, Sanofi-Aventis), semaglutide (Ozempic, Rybelsus

Italy commands a 14.3% share in 2025, projected to reach 14.5% by 2035, while Spain accounts for 11.2% in 2025, expected to reach 11.4% by 2035

Healthcare professionals should educate patients thoroughly on proper technique, and patients should feel empowered to ask questions or request refresher training at any time

Protect your muscles through resistance training and a balanced diet rich in protein